Pancreatitis with pancreatic tail swelling associated with incretin-based therapies detected radiologically in two cases of diabetic patients with end-stage renal disease

Internal Medicine

Volumn 51, Issue 21, 2012, Pages 3045-3049

  Nakata, Hirosuke ^a   Sugitani, Seita ^a   Yamaji, Shuhei ^a   Otsu, Satoko ^a   Higashi, Yoshihito ^a   Ohtomo, Yumiko ^a   Inoue, Gen ^a  

^a JAPANESE RED CROSS WAKAYAMA MEDICAL CENTER   (Japan)

Author keywords

Diabetes; End stage renal disease; Incretin based therapies; Pancreatitis

Indexed keywords

ALPHA AMYLASE PANCREAS ISOENZYME; AMYLASE; BERAPROST; BROTIZOLAM; CA 19-9 ANTIGEN; CALCIUM CARBONATE; CILOSTAZOL; HEMOGLOBIN A1C; INCRETIN; INSULIN; LIRAGLUTIDE; NICORANDIL; RABEPRAZOLE; TRIACYLGLYCEROL LIPASE; VILDAGLIPTIN;

AGED; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIALYSIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GALLSTONE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERAMYLASEMIA; INSULIN BLOOD LEVEL; KIDNEY FAILURE; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREATITIS; SWELLING;

ADAMANTANE; AGED; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; KIDNEY FAILURE, CHRONIC; MAGNETIC RESONANCE IMAGING; MALE; NITRILES; PANCREATITIS; PYRROLIDINES; RENAL DIALYSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84869138184     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.51.7876     Document Type: Article

References (19)

1. Marre M, Shaw J, Brändle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 26: 268-278, 2009.
2. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32: 84-90, 2009.
3. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373: 473-481, 2009.
4. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 32: 1224-1230, 2009.
5. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 52: 2046-2055, 2009.
6. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374: 39-47, 2009.
7. Girgis CM, Champion BL. Vildagliptin-induced acute pancreatitis. Endocr Pract 17: e48-e50, 2011.
8. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 32: 834-838, 2009.
9. Lai SW, Muo CH, Liao KF, Sung FC, Chen PC. Risk of acute pancreatitis in type 2 diabetes and risk reduction on anti-diabetic drugs: a population-based cohort study in Taiwan. Am J Gastroenterol 106: 1697-1704, 2011.
10. Jeong KH, Yoo BK. The efficacy and safety of liraglutide. Int J Clin Pharm 33: 740-749, 2011.
11. Cai L, Cai Y, Lu ZJ, Zhang Y, Liu P. The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. J Clin Pharm Ther 37: 386-398, 2011.
12. Lukashevich V, Schweizer A, Shao Q, Groop PH, Kothny W. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab 13: 947-954, 2011.
13. Kashiwagi A, Kasuga M, Araki E, et al. International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabete Invest 3: 39-40, 2012.
14. Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol 68: 898-905, 2009.
15. Lee PH, Stockton MD, Franks AS. Acute pancreatitis associated with liraglutide. Ann Pharmacother 45: e22, 2011.
16. Kristiansen L, Grønbaek M, Becker U, Tolstrup JS. Risk of pancreatitis according to alcohol drinking habits: a population-based cohort study. Am J Epidemiol 168: 932-937, 2008.
17. Terumi K, Atsutake O. Autoimmune pancreatitis: proposal of IgG4-related sclerosing disease. J Gastroenterol 41: 613-625, 2006.
18. Taniguchi T, Seko S, Azuma K, et al. Autoimmune pancreatitis detected as a mass in the tail of the pancreas. J Gastroenterol Hepatol 15: 461-464, 2000.
19. Tatarkiewicz K, Smith PA, Sablan EJ, et al. Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents. Am J Physiol Endocrinol Metab 299: E1076-E1086, 2010.